Developer docs
API playgroundTry for free, no card

Search company profiles

Nuclera

Full company profile

uuid0000ccs

Namestring
Nuclera
Legal namestring
Nuclera
Websiteurl
nuclera.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Nuclera is a Cambridge, UK-based biotechnology company that has developed eProtein Discovery, a benchtop multiplex protein screening system integrating digital microfluidics (electrowetting-on-dielectric) with cell-free protein synthesis (CFPS). Founded in 2013 by Michael Chen, Jiahao Huang, and Gordon Herling-McInroy at the University of Cambridge, the company acquired E Ink's digital microfluidics unit in 2021 to consolidate the core IP that underpins its platform. The system automates nanoliter-scale protein expression, on-cartridge fluorescence quantification, and purification across up to 192 datapoints per 24-hour run, delivering assay-ready proteins in 48 hours and addressing difficult-to-express targets including membrane proteins, GPCRs, and challenging soluble proteins. An AlphaFold2-integrated cloud software module supports AI-guided protein variant design.

Nuclera monetizes through a razor-and-blade model consisting of instrument sales (the eProtein Discovery benchtop system), recurring consumables (single-use digital microfluidic cartridges and proprietary reagent suites), and a recently launched fee-for-service Antibody Screening offering priced at approximately $100 per antibody variant with 14-business-day turnaround. Go-to-market combines direct enterprise field sales (engaging pharma and biotech R&D leaders), an emerging distributor network across APAC and the Middle East, and a service channel for AI/ML-driven antibody discovery teams that lack instrument access. Named customers span biopharma (AstraZeneca, AbbVie), ag-biotech (Bayer Crop Science, Syngenta), CROs (Domainex), and academic institutions (Harvard CMI, Imperial College London, National Taiwan University, National Cheng Kung University).

The company has raised approximately $145M in total funding across seed, Series A, multiple Series B tranches, a $75M Series C in 2024 led by Elevage Medical Technologies, and a $12M Series C extension in January 2026, with E Ink remaining its largest strategic shareholder. Recent strategic priorities include commercial scaling of the antibody workflow, geographic expansion into APAC and the Middle East, and partnerships with Cytiva and leadXpro to extend the platform into integrated bioprocessing and AI-guided structure-based drug design.

Short descriptiontext

Nuclera provides the eProtein Discovery benchtop system, combining digital microfluidics and cell-free protein synthesis to deliver multiplex protein screening and assay-ready proteins in 48 hours. It serves biopharma, ag-biotech, CROs, and academic researchers with instruments, consumables, and antibody screening services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell-free protein synthesis, digital microfluidics, protein screening instruments, membrane protein expression, antibody discovery services
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Protein Expression Systems
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1eProtein Discovery System (Instrument)
TypeHardware Sales
Description

Sale of the eProtein Discovery benchtop instrument, which orchestrates the multiplex protein screening workflow with automated digital microfluidics. The instrument is sold directly to pharmaceutical companies, biotech firms, academic institutions, and CROs.

nuclera.com
2Consumables (Cartridges and Reagents)
TypeSubscription Recurring
Description

Recurring revenue from single-use consumable cartridges (digital microfluidic cartridges) and reagent suites for DNA preparation, protein expression screening, purifiability assessment, and off-cartridge scale-up. Cartridges are single-use; reagents are replenished per run.

nuclera.com
3Antibody Screening Services
TypeProfessional Services
Description

Fee-for-service antibody screening packages. The 96-Plex Triage Screen (~14 business days turnaround) includes DNA synthesis, binary expression/binding screening, and SPR on 5 focused binders at ~$100 per antibody. Extended SPR profiling at ~$200 per antibody adds 2-3 business days.

nuclera.com
4Protein Expression and Purification Services
TypeProfessional Services
Description

Expression and purification services using the eProtein Discovery platform, enabling researchers to access the technology without purchasing the system outright.

nuclera.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
196-Plex Triage Screen: ~$100 per antibody variant, delivering binding data in ~14 business days
ModelUnit PricingBilling cadencePay-as-you-go
Notes

96-Plex Triage Screen at ~$100 per antibody variant includes: DNA sourcing and preparation, 96-plex binary expression data, 96-plex binary binding classification, single-cycle SPR on 5 confirmed hits, and decision-ready PDF + raw data files. Introductory pricing subject to change.

nuclera.com
2Extended SPR Profiling: ~$200 per antibody variant, adds 2-3 business days to timeline
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Extended SPR Profiling at ~$200 per variant adds: full-length CFPS IgG1 expression and single-cycle SPR kinetics on expanded binder set beyond the initial 5 focused hits.

nuclera.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1eProtein Discovery™
Description

The company's flagship desktop protein screening system combining digital microfluidics with cell-free protein synthesis for rapid multiplex protein expression and characterization.

nuclera.com
+1 more record
Core offering1 text field

Nuclera develops the eProtein Discovery system, a benchtop multiplex protein screening platform that combines digital microfluidics with cell-free protein synthesis. The system enables rapid expression, screening, and purification of proteins in approximately 48 hours, targeting antibody discovery, membrane protein research, and other protein engineering applications for pharmaceutical and biotechnology researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • From DNA to assay-ready protein in 48 hours
+8 more records
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-19
Description

Scientific partnership announced February 2026 to accelerate structure-based drug design for complex membrane proteins. Integrates Nuclera's eProtein Discovery cell-free protein synthesis technology with leadXpro's AI/ML-driven construct design and structural characterization expertise. Creates an AI-guided, iterative, end-to-end workflow linking in silico design with rapid experimental multiplex screening. The partnership will inform future integration of AI/ML capabilities into Nuclera's product portfolio.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-28
Description

Collaboration announced in 2025 focused on accelerating protein production, purification, and characterization for drug research and development. The companies demonstrated the ability to produce and analyze key proteins within five days, significantly faster than traditional methods.

Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-06-06
Description

Independent experts from Imperial College London serve as evaluators for the Innovate UK grant-funded projects supporting eProtein Discovery platform development. Dr Konstantinos Beis at Imperial has also independently tested and validated the eProtein Discovery system for membrane protein quality.

Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-06-06
Description

Independent experts from Diamond Light Source serve as evaluators for Innovate UK grant-funded projects supporting eProtein Discovery platform development and manufacturing capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-12
Description

Nuclera acquired E Ink's digital microfluidics unit in May 2021, including intellectual property, equipment, and scientists. E Ink became Nuclera's largest strategic shareholder as part of the transaction, consolidating IP in the biotechnology sector and establishing Nuclera's US subsidiary in Boston, MA.

Strategic tierSupportingTypeTechnology or Integration
Description

Domainex installed the eProtein Discovery System as the first CRO implementation, demonstrating the system's capability for CRO platform integration.

7Show Chung Ho / YFY Academy
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Show Chung Ho (President of YFY Academy and Founder of E Ink Holdings) purchased and donated eProtein Discovery systems to National Taiwan University and National Cheng Kung University, representing Nuclera's first commercial sales in Asia.

news-medical.net
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global life sciences tools leader offering the Gibco ExpiCHO and Expi293 protein expression systems alongside ÄKTA purification systems. Thermo Fisher dominates protein production workflow tooling for pharma and biotech with deep installed bases, making it the primary competitive incumbent for Nuclera's eProtein Discovery platform.

TypeBroad incumbent
Description

Global bioprocessing leader offering protein purification and chromatography systems (ÄKTA) plus cell line development tools. Cytiva is both a Nuclera collaboration partner (May 2025) and a partial competitor in the protein production workflow, with comparable enterprise pharma accounts and complementary product portfolios.

TypeBroad incumbent
Description

Life sciences research and clinical diagnostics company offering NGC chromatography systems, BioLogic protein purification, and droplet-based digital biology tools. Bio-Rad's protein expression and purification product lines serve overlapping pharma and academic customers as Nuclera.

TypeDirect peer
Description

DNA synthesis platform company providing synthetic genes, antibody libraries, and oligo pools that serve as critical inputs for protein engineering workflows. Twist's high-throughput DNA synthesis powers AI-driven antibody discovery pipelines that consume Nuclera's screening services, making it both an upstream enabler and a workflow-adjacent peer.

TypeDirect peer
Description

AI-driven antibody discovery platform operating end-to-end from target identification to preclinical candidates. AbCellera addresses the same AI antibody discovery bottleneck Nuclera targets and serves overlapping pharma customers, though with a therapeutic development focus rather than a screening tools offering.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company pioneering cell-free protein synthesis (XpressCF) for therapeutic antibody and cytokine manufacturing. Sutro's proprietary cell-free expression platform is the closest direct technical comparator to Nuclera's CFPS technology, though focused on internal therapeutic production rather than platform sales.

TypeEmerging player
Description

Synthetic biology platform offering cell engineering and protein production services at scale across pharma, agriculture, and industrial biotech. Ginkgo's Codebase of engineered organisms and high-throughput screening capabilities partially overlap with Nuclera's protein prototyping value proposition for biotech R&D customers.

TypeDirect peer
Description

Life sciences tools company specializing in microfluidics-based mass cytometry (CyTOF) and genomics (Biomark HD) systems. Standard BioTools shares Nuclera's microfluidics heritage and life sciences research customer base, though focuses on single-cell analysis rather than protein expression.

TypeBroad incumbent
Description

Major provider of protein analysis, purification, and expression reagents including the HaloTag and TNT cell-free protein synthesis systems. Promega's TnT coupled transcription/translation kits are a competing cell-free expression option used by overlapping academic and biotech customers.

TypeEmerging player
Description

Life sciences tools company offering the Beacon optofluidic platform for single-cell screening and antibody discovery workflows. PhenomeX addresses similar antibody discovery and cell biology applications as Nuclera through an alternative microfluidic architecture, serving overlapping biotech customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nuclera

Protein Expression Systemsnuclera.com

Nuclera provides the eProtein Discovery benchtop system, combining digital microfluidics and cell-free protein synthesis to deliver multiplex protein screening and assay-ready proteins in 48 hours. It serves biopharma, ag-biotech, CROs, and academic researchers with instruments, consumables, and antibody screening services.

What Nuclera does

Nuclera is a Cambridge, UK-based biotechnology company that has developed eProtein Discovery, a benchtop multiplex protein screening system integrating digital microfluidics (electrowetting-on-dielectric) with cell-free protein synthesis (CFPS). Founded in 2013 by Michael Chen, Jiahao Huang, and Gordon Herling-McInroy at the University of Cambridge, the company acquired E Ink's digital microfluidics unit in 2021 to consolidate the core IP that underpins its platform. The system automates nanoliter-scale protein expression, on-cartridge fluorescence quantification, and purification across up to 192 datapoints per 24-hour run, delivering assay-ready proteins in 48 hours and addressing difficult-to-express targets including membrane proteins, GPCRs, and challenging soluble proteins. An AlphaFold2-integrated cloud software module supports AI-guided protein variant design.

Nuclera monetizes through a razor-and-blade model consisting of instrument sales (the eProtein Discovery benchtop system), recurring consumables (single-use digital microfluidic cartridges and proprietary reagent suites), and a recently launched fee-for-service Antibody Screening offering priced at approximately $100 per antibody variant with 14-business-day turnaround. Go-to-market combines direct enterprise field sales (engaging pharma and biotech R&D leaders), an emerging distributor network across APAC and the Middle East, and a service channel for AI/ML-driven antibody discovery teams that lack instrument access. Named customers span biopharma (AstraZeneca, AbbVie), ag-biotech (Bayer Crop Science, Syngenta), CROs (Domainex), and academic institutions (Harvard CMI, Imperial College London, National Taiwan University, National Cheng Kung University).

The company has raised approximately $145M in total funding across seed, Series A, multiple Series B tranches, a $75M Series C in 2024 led by Elevage Medical Technologies, and a $12M Series C extension in January 2026, with E Ink remaining its largest strategic shareholder. Recent strategic priorities include commercial scaling of the antibody workflow, geographic expansion into APAC and the Middle East, and partnerships with Cytiva and leadXpro to extend the platform into integrated bioprocessing and AI-guided structure-based drug design.

Nuclera firmographics

Firmographics
Name
Nuclera
Legal name
Nuclera
Website
https://nuclera.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Nuclera provides the eProtein Discovery benchtop system, combining digital microfluidics and cell-free protein synthesis to deliver multiplex protein screening and assay-ready proteins in 48 hours. It serves biopharma, ag-biotech, CROs, and academic researchers with instruments, consumables, and antibody screening services.
Ownership category
akta.pro rank

Nuclera industry classification

Industry
Product category
Protein Expression Systems
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Cell-free protein synthesis
  • Digital microfluidics
  • Protein screening instruments
  • Membrane protein expression
  • Antibody discovery services

Where Nuclera is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Nuclera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. eProtein Discovery System (Instrument): Sale of the eProtein Discovery benchtop instrument, which orchestrates the multiplex protein screening workflow with automated digital microfluidics. The instrument is sold directly to pharmaceutical companies, biotech firms, academic institutions, and CROs.
  2. Consumables (Cartridges and Reagents): Recurring revenue from single-use consumable cartridges (digital microfluidic cartridges) and reagent suites for DNA preparation, protein expression screening, purifiability assessment, and off-cartridge scale-up. Cartridges are single-use; reagents are replenished per run.
  3. Antibody Screening Services: Fee-for-service antibody screening packages. The 96-Plex Triage Screen (~14 business days turnaround) includes DNA synthesis, binary expression/binding screening, and SPR on 5 focused binders at ~$100 per antibody. Extended SPR profiling at ~$200 per antibody adds 2-3 business days.
  4. Protein Expression and Purification Services: Expression and purification services using the eProtein Discovery platform, enabling researchers to access the technology without purchasing the system outright.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-go96-Plex Triage Screen: ~$100 per antibody variant, delivering binding data in ~14 business days
Unit PricingPay-as-you-goExtended SPR Profiling: ~$200 per antibody variant, adds 2-3 business days to timeline

Go-to-market motion4 records

Distribution channels3 records

Marketing channels7 records

Nuclera product offering

Product offering

Core offering

Nuclera develops the eProtein Discovery system, a benchtop multiplex protein screening platform that combines digital microfluidics with cell-free protein synthesis. The system enables rapid expression, screening, and purification of proteins in approximately 48 hours, targeting antibody discovery, membrane protein research, and other protein engineering applications for pharmaceutical and biotechnology researchers.

Differentiator

Problem solved

Functional benefit

Brands

  • eProtein Discovery™: The company's flagship desktop protein screening system combining digital microfluidics with cell-free protein synthesis for rapid multiplex protein expression and characterization.
  • eProtein Discovery Antibody Services

Quantifiable outcome

  • From DNA to assay-ready protein in 48 hours
  • +8 more outcomes

Companies that use Nuclera

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles3 records

Nuclera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature9 records

Nuclera partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and supporting.

  • leadXprocoreStrategic or Co-development Partner · 19 February 2026Scientific partnership announced February 2026 to accelerate structure-based drug design for complex membrane proteins. Integrates Nuclera's eProtein Discovery cell-free protein synthesis technology with leadXpro's AI/ML-driven construct design and structural characterization expertise. Creates an AI-guided, iterative, end-to-end workflow linking in silico design with rapid experimental multiplex screening. The partnership will inform future integration of AI/ML capabilities into Nuclera's product portfolio.
  • CytivacoreStrategic or Co-development Partner · 28 May 2025Collaboration announced in 2025 focused on accelerating protein production, purification, and characterization for drug research and development. The companies demonstrated the ability to produce and analyze key proteins within five days, significantly faster than traditional methods.
  • Imperial College LondonsupportingImplementation/ SI/ Consulting Partner · 6 June 2024Independent experts from Imperial College London serve as evaluators for the Innovate UK grant-funded projects supporting eProtein Discovery platform development. Dr Konstantinos Beis at Imperial has also independently tested and validated the eProtein Discovery system for membrane protein quality.
  • Diamond Light SourcesupportingImplementation/ SI/ Consulting Partner · 6 June 2024Independent experts from Diamond Light Source serve as evaluators for Innovate UK grant-funded projects supporting eProtein Discovery platform development and manufacturing capabilities.
  • E InkcoreStrategic or Co-development Partner · 12 May 2021Nuclera acquired E Ink's digital microfluidics unit in May 2021, including intellectual property, equipment, and scientists. E Ink became Nuclera's largest strategic shareholder as part of the transaction, consolidating IP in the biotechnology sector and establishing Nuclera's US subsidiary in Boston, MA.
  • DomainexsupportingTechnology or IntegrationDomainex installed the eProtein Discovery System as the first CRO implementation, demonstrating the system's capability for CRO platform integration.
  • Show Chung Ho / YFY AcademysupportingChannel Partner/ Reseller/ DistributorShow Chung Ho (President of YFY Academy and Founder of E Ink Holdings) purchased and donated eProtein Discovery systems to National Taiwan University and National Cheng Kung University, representing Nuclera's first commercial sales in Asia.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Nuclera competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific: Global life sciences tools leader offering the Gibco ExpiCHO and Expi293 protein expression systems alongside ÄKTA purification systems. Thermo Fisher dominates protein production workflow tooling for pharma and biotech with deep installed bases, making it the primary competitive incumbent for Nuclera's eProtein Discovery platform.
  • Cytiva: Global bioprocessing leader offering protein purification and chromatography systems (ÄKTA) plus cell line development tools. Cytiva is both a Nuclera collaboration partner (May 2025) and a partial competitor in the protein production workflow, with comparable enterprise pharma accounts and complementary product portfolios.
  • Bio-Rad Laboratories: Life sciences research and clinical diagnostics company offering NGC chromatography systems, BioLogic protein purification, and droplet-based digital biology tools. Bio-Rad's protein expression and purification product lines serve overlapping pharma and academic customers as Nuclera.
  • Promega Corporation: Major provider of protein analysis, purification, and expression reagents including the HaloTag and TNT cell-free protein synthesis systems. Promega's TnT coupled transcription/translation kits are a competing cell-free expression option used by overlapping academic and biotech customers.

Direct peers

  • Twist Bioscience: DNA synthesis platform company providing synthetic genes, antibody libraries, and oligo pools that serve as critical inputs for protein engineering workflows. Twist's high-throughput DNA synthesis powers AI-driven antibody discovery pipelines that consume Nuclera's screening services, making it both an upstream enabler and a workflow-adjacent peer.
  • AbCellera Biologics: AI-driven antibody discovery platform operating end-to-end from target identification to preclinical candidates. AbCellera addresses the same AI antibody discovery bottleneck Nuclera targets and serves overlapping pharma customers, though with a therapeutic development focus rather than a screening tools offering.
  • Sutro Biopharma: Clinical-stage biopharmaceutical company pioneering cell-free protein synthesis (XpressCF) for therapeutic antibody and cytokine manufacturing. Sutro's proprietary cell-free expression platform is the closest direct technical comparator to Nuclera's CFPS technology, though focused on internal therapeutic production rather than platform sales.
  • Standard BioTools (formerly Fluidigm): Life sciences tools company specializing in microfluidics-based mass cytometry (CyTOF) and genomics (Biomark HD) systems. Standard BioTools shares Nuclera's microfluidics heritage and life sciences research customer base, though focuses on single-cell analysis rather than protein expression.

Emerging players

  • Ginkgo Bioworks: Synthetic biology platform offering cell engineering and protein production services at scale across pharma, agriculture, and industrial biotech. Ginkgo's Codebase of engineered organisms and high-throughput screening capabilities partially overlap with Nuclera's protein prototyping value proposition for biotech R&D customers.
  • PhenomeX (formerly Berkeley Lights): Life sciences tools company offering the Beacon optofluidic platform for single-cell screening and antibody discovery workflows. PhenomeX addresses similar antibody discovery and cell biology applications as Nuclera through an alternative microfluidic architecture, serving overlapping biotech customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Nuclera social profiles

Digital presence

Nuclera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nuclera leadership team

Management profile

Number of profiles

Profiles11 records

Nuclera subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nuclera funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nuclera M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuclera

What does Nuclera do?

Nuclera develops the eProtein Discovery system, a benchtop multiplex protein screening platform that combines digital microfluidics with cell-free protein synthesis. The system enables rapid expression, screening, and purification of proteins in approximately 48 hours, targeting antibody discovery, membrane protein research, and other protein engineering applications for pharmaceutical and biotechnology researchers.

Is Nuclera a public or private company?

Nuclera is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nuclera founded?

Nuclera was founded in 2013. It employs 101 to 250 people.

Where is Nuclera based?

Nuclera is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Nuclera make money?

Four revenue lines are on record. eProtein Discovery System (Instrument) is the primary driver. The others are consumables (Cartridges and Reagents), antibody Screening Services and protein Expression and Purification Services.

Who are Nuclera's main competitors?

Broad incumbents on record are Thermo Fisher Scientific, Cytiva, Bio-Rad Laboratories and Promega Corporation. Direct peers are Twist Bioscience, AbCellera Biologics, Sutro Biopharma and Standard BioTools (formerly Fluidigm). Emerging players are Ginkgo Bioworks and PhenomeX (formerly Berkeley Lights).

Does Nuclera have an API?

No public API is recorded for Nuclera.

What industry is Nuclera in?

Nuclera's product category is Protein Expression Systems. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalNuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug targetNuclera and University of Cambridge researchers published a preprint showing a 3.38 Å cryo-EM structure of an engineered human adenosine A2A receptor complex, produced in four days using cell-free synthesis and nanodiscs. The workflow was also applied to 12 additional GPCRs, including six orphan receptors, demonstrating broader applicability for structural biology and drug discovery.Business Wire BlogNuclera and University of Cambridge Researchers Demonstrate Rapid Structural Analysis of Challenging Drug TargetResearchers at Nuclera and the University of Cambridge published a preprint on bioRxiv reporting a 3.38 Å cryo-EM structure of an adenosine A2A receptor complex, achieved in four days from gene assembly to sample preparation. The workflow also produced and purified 12 additional GPCRs, including six orphan receptors, demonstrating its applicability across diverse targets.FinancialContent Business PageNuclera and University of Cambridge Researchers Demonstrate Rapid Structural Analysis of Challenging Drug TargetResearchers at Nuclera and the University of Cambridge published a preprint showing a 3.38 Å cryo-EM structure of an adenosine A2A receptor complex, achieved in four days from gene assembly to sample preparation. The workflow also produced and purified 12 additional GPCRs, including six orphan receptors, demonstrating its broader applicability.The Mass Spectrometry Web PortalNuclera–Raimond C: management, 202609– CEO before Thermo Fisher + Olink Proteomics + PerkinElmer + Agilent + AffymetrixNuclera appointed Carl Raimond as CEO, effective immediately, and moved co-founder Michael Chen to Chief Scientific and Business Officer. Raimond previously led Olink Proteomics through its $3.1 billion acquisition by Thermo Fisher. The leadership change supports Nuclera's expansion of its cell-free protein synthesis platform.SelectScienceNuclera debuts AI-ready antibody screening serviceNuclera, a biotechnology company enabling rapid access to high-quality proteins, has launched a new antibody screening service designed to accelerate AI-driven antibody discovery. The service uses 96-plex binary cell-free expression and binding assays to screen full-length antibody libraries in parallel, enabling researchers to identify and eliminate non-binders early before committing to costly mammalian expression and functional testing. The launch, which follows Nuclera's Series C extension, addresses a key bottleneck in antibody discovery where traditional secondary screening methods are slow and resource-intensive.AijournNuclera Launches Antibody Triage Service to Advance AI-Driven Antibody DiscoveryNuclera, a biotechnology company headquartered in Cambridge, UK and Boston, USA, has launched an antibody screening service designed to streamline the transition from AI-generated antibody hit selection to lead optimization. The service uses 96-plex binary cell-free expression and binding assays to rapidly triage large candidate libraries, enabling early elimination of non-binders before costly mammalian expression and functional testing workflows. The launch follows the company's Series C extension to $87 million and represents a strategic step toward addressing a key bottleneck in AI-driven antibody discovery by converting large in silico-generated libraries into experimental binding data.The ScientistNuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteinsNuclera and leadXpro announced a scientific partnership on February 19, 2026 to accelerate structure-based drug design for complex membrane proteins. The collaboration integrates Nuclera's eProtein Discovery cell-free protein synthesis technology with leadXpro's AI/ML-driven construct design and structural characterization expertise to establish an AI-guided, iterative workflow that links in silico design with rapid experimental multiplex screening. The partnership will also inform future integration of AI/ML capabilities into Nuclera's product portfolio and strengthen leadXpro's platform for producing and characterizing difficult membrane protein targets.PharmaTimesNuclera and leadXpro partner to accelerate structure‑based drug designNuclera and leadXpro announced a scientific partnership to improve access to and study of challenging membrane protein drug targets, combining Nuclera's rapid multiplex screening technology with leadXpro's AI/ML-driven construct design and structural biology expertise. The collaboration will integrate Nuclera's eProtein Discovery System with leadXpro's cryo-EM capabilities to create an iterative AI-guided workflow that links in silico design with experimental screening. The partnership aims to de-risk and accelerate membrane protein drug discovery programs while supporting future integration of predictive design into Nuclera's product portfolio.PharmiWeb.comNuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane ProteinsNuclera, a biotechnology company, and leadXpro, a specialist in structure-based drug discovery for membrane proteins, have announced a scientific partnership to advance therapeutic development for challenging membrane protein targets. The collaboration integrates Nuclera's eProtein Discovery rapid multiplex membrane protein screening technology with leadXpro's AI/ML-driven construct design and structural biology expertise to create an AI-guided, iterative, end-to-end workflow linking in silico design with experimental screening. The partnership aims to shorten the path to structural and biophysical insights for structure-based drug discovery and will inform future integration of AI/ML capabilities into Nuclera's product portfolio.SelectScienceNuclera extends Series C funding to $87M to advance antibody engineeringNuclera announced a $12 million financing extension to its Series C round, bringing total Series C funding to $87 million, to accelerate integration of antibody expression and binding validation into its eProtein Discovery benchtop system. The expanded platform will enable researchers to perform end-to-end expression, purification, and binding validation of full-format antibodies on an integrated, high-throughput system. The company stated this positions it to become a foundational platform for AI-enabled protein and antibody engineering in biologics discovery.